PURSPEC Technologies
Develops portable mass spectrometry instruments for point-of-care diagnostics and structural lipidomics.
Website: https://www.purspec.com/
Cover Block
| Name | PURSPEC Technologies |
| Tagline | Develops portable mass spectrometry instruments for point-of-care diagnostics and structural lipidomics. |
| Headquarters | West Lafayette, Indiana, USA |
| Founded | 2014 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Series A (total disclosed ~$13,810,000) |
Links
- Website: https://www.purspec.com/
- LinkedIn: https://www.linkedin.com/company/purspec-technologies-inc
- YouTube: https://www.youtube.com/watch?v=wmLSkqmpZUg
The Short Version
PURSPEC Technologies is developing portable mass spectrometers to bring laboratory-grade chemical analysis directly to the point of care [PURSPEC, retrieved 2024]. Founded in 2014 by Purdue University professor Zheng Ouyang, the company leverages academic research into miniature instrumentation and ambient ionization to create systems for rapid, on-site diagnostics [Purdue University, 2017]. Its wedge combines portability with a focus on advanced structural lipidomics [PURSPEC, retrieved 2026].
Ouyang's technical authority and collaborations with Purdue and Tsinghua University provide a foundation for R&D, with an operational footprint bifurcated between a US entity and a larger team in China [LinkedIn, retrieved 2024] [PURSPEC, retrieved 2026]. Capitalization includes a Series A round completed in May 2024, reported at approximately $13.8 million [CompanyCheck / SPEEDA-style profile, May 2024] [Crunchbase, 2024].
Data Accuracy: YELLOW -- Core company claims and founding story are well-sourced; funding details and headcount show inconsistencies across providers.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Series A (total disclosed ~$13,810,000) |
The Company in Brief
PURSPEC Technologies was founded in 2014 by Professor Zheng Ouyang during his tenure at Purdue University [PURSPEC, retrieved 2024]. Headquartered in West Lafayette, Indiana, the company develops portable, point-of-care diagnostic instruments based on miniature mass spectrometry and ambient ionization [Purdue University, 2017]. A Series A financing was completed in May 2024, reported in the range of $13.8 million to $13.9 million [CompanyCheck / SPEEDA-style profile, May 2024][PitchBook, retrieved 2024].
Data Accuracy: YELLOW -- Founding details are confirmed by the company and university; funding amount is reported by multiple sources but with minor discrepancies.
What They Have Built
PURSPEC's MiniMS platform is designed to perform complex mixture analysis with minimal sample preparation, using ambient ionization techniques for direct sampling [PURSPEC, retrieved 2024]. The product suite targets clinical diagnostics, food safety, environmental monitoring, and forensics [PURSPEC, retrieved 2024] [PURSPEC, retrieved 2026]. A specialized focus is advanced structural lipidomics, including double-bond positioning for lipids [PURSPEC, retrieved 2024]. The company maintains collaborations with Tsinghua University and Purdue University to advance these applications [PURSPEC, retrieved 2026].
Data Accuracy: YELLOW -- Product claims and applications are consistently described across the company's website and academic partnerships, but detailed technical specifications and independent performance validations are not publicly cited.
Market Size and Demand
Global clinical mass spectrometry market was valued at approximately $2.5 billion in 2023 and is projected to grow at a compound annual growth rate of 8.4% through 2030 [Grand View Research, 2024].
| Metric | Value |
|---|---|
| Clinical Mass Spectrometry Market 2023 | $2.5B |
| Projected CAGR 2024-2030 | 8.4% |
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broad market report; specific TAM for the portable/POC segment is not independently verified.
Who Else Is Fighting for This
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| PURSPEC Technologies | Portable MS for POC diagnostics & structural lipidomics | Series A (~$13.8M) | Academic spinout with dual US/China presence; focus on ambient ionization. |
| 908 Devices | Handheld & portable chemical detection | Public (NASDAQ: MASS) | Commercialized MAVERICK and MX908 devices. |
| Bruker Corporation | High-performance mass spectrometers | Public (NASDAQ: BRKR) | Dominant share in high-end research MS. |
| Waters Corporation | LC/MS systems | Public (NYSE: WAT) | Industry standard for chromatography-coupled MS. |
| PerkinElmer Inc. | Analytical instruments | Public (NYSE: PKI) | Strength in clinical diagnostics. |
Data Accuracy: YELLOW -- Competitor identification is from structured data; differentiation and positioning are inferred from public company materials and sector analysis.
Opportunity
PURSPEC aims to become the category-defining platform for point-of-care mass spectrometry. The technology addresses bottlenecks in clinical diagnostics, food safety, and environmental monitoring [Purdue University, 2017]. The company's focus on structural lipidomics provides a data-intensive niche [PURSPEC].
Data Accuracy: YELLOW -- Opportunity analysis is based on company-stated application sectors and academic collaboration.
Sources
- [PURSPEC, retrieved 2024] Home - PURSPEC | https://www.purspec.com/
- [Purdue University, 2017] Purdue Research Park: Purspec Technologies, Inc. | https://www.prf.org/researchpark/companies/p-companies/Purspec%20Technologies,%20Inc..html
- [PURSPEC, retrieved 2026] About Us - PURSPEC | https://www.purspec.com/about/about-us/
- [LinkedIn, retrieved 2024] PURSPEC Technologies Inc. | LinkedIn | https://www.linkedin.com/company/purspec-technologies-inc
- [CompanyCheck / SPEEDA-style profile, May 2024] PURSPEC Technologies - CompanyCheck / SPEEDA-style profile | https://www.cbinsights.com/company/purspec-technologies
- [Crunchbase, 2024] PURSPEC Technologies - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/purspec-technologies
- [PitchBook, retrieved 2024] PURSPEC Technologies - PitchBook Profile | https://www.cbinsights.com/company/purspec-technologies
- [Grand View Research, 2024] Clinical Mass Spectrometry Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/clinical-mass-spectrometry-market
- [PMC, 2026] Miniature mass spectrometers are recognized, as exemplified by instruments from Advion, BaySpec, FLIR, Inficon, MassTech, PerkinElmer, PurSpec, 908 Devices, and Waters | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/
Articles about PURSPEC Technologies
- PURSPEC Technologies Is Shrinking the Mass Spectrometer for the Clinic — The academic spinout, backed by $13.8 million, aims to move complex lipid analysis from the central lab to the patient's bedside.